Products for Research Use Only

Indacaterol

CAT: 0804-HY-14299-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14299-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder) . Indacaterol can also be used in cardiovascular disease research[1][2].
CAS Number
312753-06-3
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Adrenergic Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer; Endocrinology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/indacaterol.html
Purity
99.98
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
OC1=CC=C([C@@H](O)CNC2CC(C=C(CC)C(CC)=C3)=C3C2)C4=C1NC(C=C4)=O
Molecular Formula
C24H28N2O3
Molecular Weight
392.49
Precautions
H302, H312, H332
References & Citations
[1]Lee SU, et al. Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation. Mol Cells. 2014 Aug;37 (8) :585-91. |[2]Calzetta L, et al. Effects of the new ultra-long-acting β2-AR agonist indacaterol in chronic treatment alone or in combination with the β1-AR blocker metoprolol on cardiac remodelling. 2015.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
β adrenergic receptor
Citation 01
BioRxiv. 2025 May 29:2025.05.28.656715.|Drug Test Anal. 2021 Feb;13 (2) :283-298.|J Chromatogr A. 2024 Feb 22:1717:464696.|J Neuroimmunol. 2019 Jul 15:332:37-48.|Pharmaceutics. 2020 Feb 11;12 (2) :145.